Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Zymeworks Inc. (NYSE:ZYME - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $21.00.

ZYME has been the subject of several analyst reports. TD Securities initiated coverage on shares of Zymeworks in a research note on Tuesday, May 20th. They issued a "buy" rating for the company. Lifesci Capital initiated coverage on shares of Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price target for the company. Citigroup increased their price target on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, March 7th. TD Cowen initiated coverage on shares of Zymeworks in a research note on Tuesday, May 20th. They issued a "buy" rating for the company. Finally, HC Wainwright increased their price target on shares of Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Monday, March 10th.

Zymeworks Trading Down 1.2%

ZYME stock opened at $12.48 on Friday. The company has a market cap of $868.32 million, a price-to-earnings ratio of -8.32 and a beta of 1.18. Zymeworks has a 12 month low of $8.21 and a 12 month high of $17.70. The firm has a 50-day moving average of $12.05 and a two-hundred day moving average of $12.90.

Zymeworks (NYSE:ZYME - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. The company had revenue of $27.11 million during the quarter, compared to the consensus estimate of $20.65 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. Zymeworks's quarterly revenue was up 170.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.42) EPS. As a group, equities analysts forecast that Zymeworks will post -1.39 earnings per share for the current year.

Insider Transactions at Zymeworks

In related news, Director Ecor1 Capital, Llc acquired 196,438 shares of the business's stock in a transaction dated Friday, April 4th. The shares were acquired at an average price of $11.17 per share, with a total value of $2,194,212.46. Following the completion of the transaction, the director now owns 17,699,774 shares of the company's stock, valued at $197,706,475.58. The trade was a 1.12% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have purchased 471,106 shares of company stock valued at $5,421,364. 1.92% of the stock is currently owned by company insiders.

Institutional Trading of Zymeworks

A number of large investors have recently modified their holdings of the stock. Sterling Capital Management LLC lifted its position in shares of Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock worth $25,000 after purchasing an additional 1,524 shares during the last quarter. CWM LLC lifted its position in shares of Zymeworks by 1,091.2% during the 1st quarter. CWM LLC now owns 2,299 shares of the company's stock worth $27,000 after purchasing an additional 2,106 shares during the last quarter. AlphaQuest LLC lifted its position in shares of Zymeworks by 480.2% during the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock worth $41,000 after purchasing an additional 2,324 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Zymeworks by 1,113.3% during the 1st quarter. GAMMA Investing LLC now owns 6,467 shares of the company's stock worth $77,000 after purchasing an additional 5,934 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Zymeworks during the 4th quarter worth $108,000. Hedge funds and other institutional investors own 92.89% of the company's stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.